While formal evidence remains in development, the mechanistic rationale is compelling: sustained, gentle GLP-1 receptor activation may favorably influence glucose metabolism, cardiovascular integrity, and neuroprotection, all while maintaining tolerability and adherence
There have been reports to FDA and other sources about how the concentration of these products are not clearly listed or sold as [advertised], Neumiller said
10.1007/s00125-023-05973-w 78 SoresiM.GiannitrapaniL
SEMA SEMA, a weekly GLP-1RA developed by Novo Nordisk, enhances its affinity for albumin by incorporating two amino acids into human GLP-1, resulting in resistance to degradation in the body
Real People
This is why a primary concern with microdosing is that people may not obtain the necessary amount of the GLP-1 drug to have the desired therapeutic outcome, such as weight loss